GIM
SMMT icon

Granahan Investment Management’s Summit Therapeutics SMMT Stock Holding History

Granahan Investment Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-185,640
Closed -$3.95M – 166
2025
Q2 		$3.95M Buy
185,640
+61,113
+49% +$1.39M 0.16% 111
2025
Q1 		$2.4M Sell
124,527
-9,305
-7% -$187K 0.12% 128
2024
Q4 		$2.39M Buy
133,832
+7,734
+6% +$150K 0.1% 144
2024
Q3 		$2.76M Buy
+126,098
New +$1.76M 0.11% 158

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Granahan Investment Management's SMMT Position: Q3 2025 in Review

Granahan Investment Management sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 185,640 shares — an estimated $3.95M sold.

Granahan Investment Management first reported a position in SMMT in Q3 2024 and held it in 4 quarters. The position peaked at $3.95M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Granahan Investment Management reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Granahan Investment Management sold 185,640 Summit Therapeutics shares in Q3 2025, an estimated $3.95M.
  • Granahan Investment Management first reported a position in Summit Therapeutics in Q3 2024 and held it in 4 quarters.
  • Granahan Investment Management's Summit Therapeutics position peaked at $3.95M in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Granahan Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.